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Introduction
Venous thrombi are rbc-rich clots that afflict 1 million Americans 
annually. The prevailing paradigm suggests rbc are incorporated 
into venous thrombi via passive trapping during intravascular fi-
brin deposition (1). However, little is known about the mechanisms 
regulating this process, or how rbc incorporation into thrombi con-
tributes to thrombus size or function.
The fibrin precursor, fibrinogen, is a plasma glycoprotein (Mr 
340 kDa) consisting of 2 Aα-chains, 2 Bβ-chains, and 2 γ-chains, 
which circulate at 2 to 5 mg/ml. During coagulation, fibrinogen is 
cleaved by thrombin and polymerized into an insoluble, but highly 
extensible and elastic (2), network. The transglutaminase factor 
XIII(a) (FXIIIa) produces ε-N-(γ-glutamyl)-lysine crosslinks be-
tween residues in the γ- and α-chains that stabilize the fibrin net-
work and are essential for clot mechanical stability and protection 
against premature dissolution during wound healing.
The C terminus of the fibrinogen γ-chain interacts with a myri-
ad of soluble and cell-associated proteins (3). In particular, previous 
studies have shown that fibrinogen residues γ390–395, located imme-
diately upstream of the FXIIIa crosslinking sites on the fibrin(ogen) 
γ-chains, mediate interactions with the CD11b subunit of CD11b/
CD18 (Mac-1). Mice with a mutation of this region (Fibγ390–396A) have 
normal fibrinogen levels and exhibit normal fibrin polymerization 
and platelet aggregation (4). However, Fibγ390–396A mice have defective 
clearance of Staphylococcus aureus (4) and are protected against auto-
inflammatory disorders (5–9). These effects are thought to stem from 
the lack of fibrin-driven leukocyte responses during inflammation.
The protransglutaminase FXIII consists of 2 catalytic subunits 
(FXIII-A) and 2 noncatalytic subunits (FXIII-B) in a noncovalent, 
heterotetramer (FXIII-A2B2, Mr, 325 kDa). FXIII-A2B2 is activated 
by thrombin-catalyzed release of a 37–amino acid activation pep-
tide from the N terminus of the FXIII-A2 subunits (10, 11) and 
calcium-mediated dissociation of FXIII-B subunits from FXIII-A2, 
yielding activated FXIII-A2 (FXIII-A2*) (12–14). Essentially all 
FXIII-A2B2 in plasma (70 nM) circulates in complex with fibrino-
gen (15, 16); however, the residues in fibrinogen that mediate 
FXIII-A2B2 binding have not been defined.
Herein, we analyzed the role of fibrinogen residues γ390–396 
in venous thrombosis. Our data indicate fibrinogen residues γ390–
396 mediate FXIII-A2B2 binding and activation and reveal a criti-
cal role for FXIIIa activity in venous thrombosis. These findings 
redefine the paradigm describing mechanisms regulating the cel-
lular composition of venous thrombi.
Results
Thrombi from Fibγ390–396A mice are smaller and have reduced rbc 
content compared with thrombi from WT mice. To determine the 
Venous thrombi, fibrin- and rbc-rich clots triggered by inflammation and blood stasis, underlie devastating, and sometimes 
fatal, occlusive events. During intravascular fibrin deposition, rbc are thought to become passively trapped in thrombi and 
therefore have not been considered a modifiable thrombus component. In the present study, we determined that activity of 
the transglutaminase factor XIII (FXIII) is critical for rbc retention within clots and directly affects thrombus size. Compared 
with WT mice, mice carrying a homozygous mutation in the fibrinogen γ chain (Fibγ390–396A) had a striking 50% reduction in 
thrombus weight due to reduced rbc content. Fibrinogen from mice harboring the Fibγ390–396A mutation exhibited reduced 
binding to FXIII, and plasma from these mice exhibited delayed FXIII activation and fibrin crosslinking, indicating these 
residues mediate FXIII binding and activation. FXIII-deficient mice phenocopied mice carrying Fibγ390–396A and produced 
smaller thrombi with fewer rbc than WT mice. Importantly, FXIII-deficient human clots also exhibited reduced rbc retention. 
The addition of FXIII to FXIII-deficient clots increased rbc retention, while inhibition of FXIII activity in normal blood reduced 
rbc retention and produced smaller clots. These findings establish the FXIII-fibrinogen axis as a central determinant in venous 
thrombogenesis and identify FXIII as a potential therapeutic target for limiting venous thrombosis.
Factor XIII activity mediates red blood cell retention  
in venous thrombi
Maria M. Aleman,1 James R. Byrnes,1 Jian-Guo Wang,1 Reginald Tran,2 Wilbur A. Lam,2 Jorge Di Paola,3 Nigel Mackman,4,5  
Jay L. Degen,6 Matthew J. Flick,6 and Alisa S. Wolberg1,4
1Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2Wallace H. Coulter Department of Biomedical Engineering,  
Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA. 3Department of Pediatrics and Human Medical Genetics and Genomics Program, University of Colorado, Denver,  
Colorado, USA. 4McAllister Heart Institute and 5Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.  
6Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists 
associated with Duke University, The University of North Carolina at Chapel Hill, 
Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by 
members of the editorial board but rather by the science editors, who consult with 
selected external editors and reviewers.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: January 27, 2014; Accepted: May 21, 2014.
Reference information: J Clin Invest. 2014;124(8):3590–3600. doi:10.1172/JCI75386.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 5 9 1jci.org   Volume 124   Number 8   August 2014
venous thrombi because of reduced rbc incorporation and/or re-
tention during thrombogenesis.
rbc are extruded from Fibγ390–396A clots during clot retraction. 
To test the hypothesis that reduced rbc content of Fibγ390–396A 
thrombi was due to a failure to retain rbc during clot formation 
and retraction, we developed an ex vivo whole blood assay in 
which whole blood is clotted with tissue factor and CaCl2. In this 
assay, clot formation is immediately followed by platelet-medi-
ated clot retraction, which is complete within 60 to 90 minutes. 
Initially, clotting proceeded similarly for both WT and Fibγ390–396A 
blood. However, compared with WT clots, fully retracted Fibγ390–396A 
clots exhibited reduced rbc retention (Figure 2, A and B), in-
creased clot retraction (Figure 2A), and reduced clot weight (Fig-
ure 2C). Consistent with observations in vivo, clot rbc content 
correlated positively and significantly with clot weight (R2 = 0.62, 
P < 0.0003). Loss of rbc from clots was not due to diminished 
platelet-mediated contraction because, in the absence of rbc, 
clot retraction was identical in WT and Fibγ390–396A platelet-rich 
plasma (PRP) (Figure 2, D and E). Loss of rbc was also not due to 
deficient interactions between fibrin(ogen) and CD11b (the mo-
lecular interaction previously shown to be deficient in Fibγ390–396A 
mice; ref. 4) because whole blood from CD11b–/– mice (21) exhib-
ited normal rbc retention during clot retraction (Supplemental 
Figure 3A). rbc extrusion was not due to a defect in rbc function; 
when we separately prepared PRP and washed rbc from WT and 
Fibγ390–396A mice and mixed WT rbc with Fibγ390–396A PRP and vice 
versa, rbc extrusion remained associated with the PRP from 
Fibγ390–396A mice (Figure 2F). When whole blood from WT and 
role of fibrinogen residues γ390–396 in venous thrombosis, we 
first used the inferior vena cava (IVC) ligation (stasis) thrombo-
sis model that produces thrombi independent of leukocyte tis-
sue factor activity (17, 18). Surprisingly, thrombi from Fibγ390–396A 
mice were 50% smaller than thrombi from WT mice 1 day after 
ligation (Figure 1A). Reduced thrombus weight was not due to 
reduced procoagulant activity; plasma from WT and Fibγ390–396A 
mice had similar thrombin generation in vitro (Supplemental 
Figure 1A; supplemental material available online with this ar-
ticle; doi:10.1172/JCI75386DS1), and circulating thrombin-anti-
thrombin (TAT) complex levels were similar in WT and Fibγ390–396A 
mice following thrombus formation in vivo (Supplemental Figure 
1B). Strikingly, however, thrombus lysates from Fibγ390–396A mice 
had significantly reduced hemoglobin (absorbance at 575 nm, 
Figure 1B) and reduced erythrocyte spectrin α1 content (Supple-
mental Figure 2), indicating that Fibγ390–396A thrombi contained 
fewer rbc than WT thrombi. Furthermore, for both WT and 
Fibγ390–396A thrombi, thrombus rbc content correlated positively 
and significantly with thrombus weight (R2 = 0.80, P < 0.0001), 
indicating rbc content is the major determinant of thrombus size. 
Western blots of thrombus lysates showed thrombi from WT and 
Fibγ390–396A mice did not differ in neutrophil, platelet, or fibrin 
content (Figure 1, C–E). Results in a second venous thrombosis 
model that involves stenosis rather than complete ligation (19, 
20) were similar; despite the typical variability in clot sizes in this 
model, Fibγ390–396A mice displayed reduced thrombus weights and 
reduced rbc presence compared with WT mice (Figure 1, F and 
G). Together, these data suggest Fibγ390–396A mice produce smaller 
Figure 1. Compared with thrombi from WT mice, thrombi from Fibγ390–396A mice are smaller and have reduced rbc content. (A) Thrombus weights 1 day 
after ligation (stasis model). (B) Total rbc content of stasis thrombus lysates, measured as hemoglobin absorbance at 575 nm. (C) Total neutrophil content 
of thrombus lysates, measured by Ly6G antigen. (D) Total platelet content of thrombus lysates, measured by CD41 antigen. (E) Total fibrin (β-chain) 
antigen of thrombus lysates. (F) Thrombus weights 1 day after ligation (stenosis model). (G) Total rbc content of stenosis thrombus lysates, measured as 
hemoglobin absorbance at 575 nm. Each dot represents an individual mouse. Lines represent means.
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fibrin(ogen) (P = 1.0, Figure 3B), indicating residues γ390–396 do 
not mediate a direct interaction between rbc and fibrin(ogen).
Fibrinogen isolated from Fibγ390–396A mice has reduced binding to 
FXIII. Since our results associated defective thrombus rbc retention 
with the mutated fibrin(ogen), we isolated fibrinogen from WT and 
Fibγ390–396A plasma by glycine precipitation and used SDS-PAGE for 
further analysis. Surprisingly, we identified 2 protein bands (Mr ~83 
and ~76 kDa) present with equal staining intensity that coprecipi-
tated with purified WT, but not Fibγ390–396A, fibrinogen (Figure 4A). 
Mass spectrometry identified these bands as the A and B subunits 
of FXIII-A2B2, and Western blotting with an anti–FXIII-A subunit 
antibody confirmed the presence of FXIII in purified WT but not 
purified Fibγ390–396A fibrinogen (Figure 4B). Since Fibγ390–396A mice 
have normal levels of circulating FXIII in plasma (Figure 4C and 
Supplemental Figure 4) and since FXIII binding to WT fibrinogen 
is well established, these data suggest plasma FXIII-A2B2 has re-
duced binding affinity for fibrinogen from Fibγ390–396A mice. Binding 
assays evaluating FXIII-A2B2 binding to adherent fibrin(ogen) sup-
port this hypothesis: compared with WT fibrin(ogen), FXIII-A2B2-
bound Fibγ390–396A fibrin(ogen) with approximately 6-fold weaker 
affinity (16 ± 4 versus 90 ± 24 nM, respectively, Figure 4D) with 
no evidence of cooperative binding to either WT or Fibγ390–396A 
fibrin(ogen) (Hill coefficients ~1). These data suggest fibrinogen 
γ-chain residues 390–396 support interactions with FXIII-A2B2.
Plasma from Fibγ390–396A mice exhibits delayed FXIII activa-
tion and delayed fibrin crosslinking. The initial characterization of 
Fibγ390–396A mice showed that purified fibrinogen from these mice 
Fibγ390–396A mice was mixed in equal parts, retracted clot weights 
were intermediate between WT and Fibγ390–396A clots (Supple-
mental Figure 3B).
Since rbc bind to platelet αIIbβ3 (22, 23), we tested the hypoth-
esis that rbc-platelet interactions mediated rbc retention in clots. 
We combined platelet-free plasma (PFP) from WT and Fibγ390–396A 
mice with washed rbc from WT mice, triggered clotting with tissue 
factor and CaCl2, and then measured rbc released from the fully 
formed clots. Under these conditions, Fibγ390–396A clots released 
more rbc than WT clots (3.6% ± 0.6% versus 1.3% ± 0.1% of initial, 
P < 0.02, n = 5). However, compared with clots formed in the pres-
ence of platelets (Figure 2F), both WT and Fibγ390–396A platelet-free 
clots released significantly (>10-fold) fewer rbc. These data show 
that platelet-mediated clot retraction promotes extrusion of rbc 
from Fibγ390–396A clots and that platelets are not required to retain 
rbc in either WT or Fibγ390–396A plasma clots. Together, these find-
ings show defective retention of rbc in clots made from blood con-
taining the mutant (Fibγ390–396A) fibrinogen.
Fibrinogen residues γ390–396 do not bind to rbc. To determine 
whether fibrinogen residues γ390–396 make up a specific motif 
that mediates rbc binding, we used a microfluidic-based adhesion 
assay to measure binding of rbc to purified, immobilized WT and 
Fibγ390–396A fibrin(ogen). Whereas rbc did not adhere to BSA-coated 
microchannels, rbc adhered to both WT and Fibγ390–396A purified 
fibrin(ogen) and remained bound even when subject to high shear 
wash rates (Figure 3A). Importantly, there were no differences in 
the percentage of rbc that remained bound to WT and Fibγ390–396A 
Figure 2. rbc are extruded from Fibγ390–396A clots during clot retraction, resulting in decreased clot weight. After clot formation, platelet contractile force 
retracts clots away from siliconized tube walls, leaving the clots surrounded by serum. (A) Image of fully retracted WT and Fibγ390–396A clots 90 minutes 
after initiation of clot formation by tissue factor and CaCl2. (B) Number of rbc present in the serum following clot retraction (n = 3). (C) Wet clot weights 
following clot retraction (n = 3). (D) Image of fully retracted PRP clots 90 minutes after initiation of clot formation. (E) Percentage retraction of PRP clots 
(n = 3). (F) Serum rbc content of retracted clots containing WT PRP with Fibγ390–396A rbc and vice versa (n = 3). Data represent mean ± SEM.
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trols (Figure 6, B and C), suggesting a role for FXIII in general cell 
retention in thrombi. However, thrombi from F13a–/– mice showed 
normal fibrin content (Figure 6D), consistent with the observa-
tion that thrombus formation in the stasis model is independent 
of leukocyte tissue factor activity (17, 18). Importantly, lysates of 
thrombi from F13a–/– mice revealed significantly reduced thrombus 
rbc content (hemoglobin [Figure 6E] and erythrocyte spectrin α1 
[Supplemental Figure 5]) compared with F13a+/+ controls. Although 
some F13a+/+ controls also produced small thrombi, the rbc density 
of these smaller thrombi was similar to that of larger thrombi from 
F13a+/+ controls (Supplemental Figure 6). Notably, the thrombus 
rbc content from both F13a–/– and F13a+/+ mice correlated positively 
and significantly with thrombus weight (R2 = 0.95, P < 0.0001).
To determine the role of FXIIIa activity in rbc retention during 
clotting, we measured rbc retention during clot retraction in whole 
blood from F13a–/– mice and F13a+/+ controls. Whole blood from 
F13a–/– mice exhibited reduced rbc retention during clot retraction 
(Figure 6F), phenocopying that seen in Fibγ390–396A clot retraction 
(Figure 6G and Figure 2, A–C). Together, these data indicate FXIII 
activity dictates rbc retention in venous thrombi.
FXIII determines rbc content and size of clots formed in human 
whole blood. “Excessive red cell fallout” during clot retraction was 
previously reported in a study of a family with congenital FXIII de-
ficiency (25); however, the finding was not pursued. To determine 
whether plasma FXIII activity is required for rbc retention in hu-
man clots, we reconstituted plasma from a FXIII-deficient human 
patient with washed platelets and rbc from healthy individuals. 
Reactions were performed in the absence and presence of exoge-
nous plasma-derived FXIII-A2B2 (Fibrogammin-P) added at doses 
recommended for prophylaxis (10 IU/kg, 0.15 IU/ml) and surgery 
(33 IU/kg, 0.5 IU/ml) and a dose to return FXIII-A2B2 levels to nor-
can be crosslinked by activated FXIII (4). However, those experi-
ments were performed with low fibrinogen (0.25 mg/ml, 10-fold 
lower than plasma levels) and high human FXIII-A2B2 (470 nM, 
6.7-fold higher than plasma levels). These conditions would have 
masked reduced binding affinity and could explain why this dif-
ference was not detected. Therefore, we measured the kinetics of 
FXIII activation and fibrin crosslinking during tissue factor–initi-
ated plasma clotting. Compared with WT, plasma from Fibγ390–396A 
mice exhibited approximately 5-fold slower conversion of FXIII-
A2B2 to FXIII-A2* (58.3 ± 19.2 versus 12.2 ± 2.5 AU/min [×10
–3], 
P < 0.04, Figure 5, A and B). Since association of FXIII-A2B2 with 
fibrin(ogen) accelerates its activation, these data are consistent 
with reduced affinity between FXIII-A2B2 and Fibγ
390–396A fibrino-
gen. Accordingly, compared with WT, plasma clots from Fibγ390–396A 
mice exhibited an approximately 6-fold reduced rate of formation 
of both γ-γ dimers (P < 0.0005, Figure 5, C and D) and high MW 
crosslinked species (P < 0.004, Figure 5, C and E), consistent with 
the delay in FXIII-A2* generation. Notably, the time course of fibrin 
crosslinking in these experiments mirrors the time frame during 
which rbc were extruded during in vitro clot retraction. Together, 
these data demonstrate a defect in FXIII-A2B2 activation and activ-
ity in Fibγ390–396A mice and suggest decreased FXIII activity permits 
rbc extrusion during clot retraction, resulting in smaller thrombi.
FXIII-deficient mice produce smaller thrombi with reduced rbc 
content. To determine the effect of FXIII on thrombus formation in 
vivo, we performed the IVC ligation stasis model on mice deficient 
in the FXIII catalytic A-subunit (F13a–/–) (24). Similar to that seen in 
Fibγ390–396A mice (Figure 1A), thrombi from F13a–/– mice had signifi-
cantly reduced weights compared with F13a+/+ controls (Figure 6A). 
Unlike in Fibγ390–396A mice, thrombi from F13a–/– mice showed re-
duced neutrophil and platelet content compared with F13a+/+ con-
Figure 3. rbc adhere to fibrin(ogen) from WT and Fibγ390–396A mice. (A) 
Adherence of rbc to BSA, WT fibrin(ogen), or Fibγ390–396A fibrin(ogen) before 
and after application of flow with a shear rate of 1000 s–1. Scale bar: 30 μm. 
(B) Quantitation of rbc adhesion after application of flow. Data represent 
mean ± SEM (n = 3). *P < 0.009, versus BSA by ANOVA.
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residues in the fibrinogen γ-chain that mediate FXIII 
zymogen binding to fibrinogen and, consequently, 
FXIII-A2B2 activation and activity. To our knowledge, 
these findings are the first to implicate these residues 
in fibrinogen’s FXIII carrier function. Finally, our find-
ings with Fibγ390–396A mice delineate the essential, syn-
chronized events governing fibrin formation, cross-
linking, and platelet-mediated clot retraction during 
venous thrombogenesis.
Venous thromboembolism and atrial fibrillation–
associated thrombosis affect millions of Americans 
each year (26, 27). Moreover, increased venous throm-
bus burden (size) is associated with increased morbidi-
ty and mortality, and decreased clot burden is associat-
ed with lower risk of recurrence (28). Consequently, an 
agent that can prevent or reduce thrombus size may be 
an attractive thromboprophylactic drug. Since FXIIIa 
inhibition decreases clot size, mechanical stability, 
and resistance to fibrinolysis, this approach would be 
expected to both decrease thrombosis and accelerate 
clot dissolution. Moreover, since in vitro studies sug-
gest rbc packing reduces diffusion within retracted 
clots (29), decreasing thrombus rbc content may also 
increase diffusion of thrombolytics into thrombi, mak-
ing FXIIIa inhibition a multipronged antithrombotic 
approach. The FXIIIa inhibitor we used in vitro is simi-
lar to another thioimidazolium derivative (L-722.151) 
that was previously evaluated in arterial thromboly-
sis models in rabbits (30) and dogs (31). Although 
L-722.151 accelerates thrombolysis, its short half-life 
(~5 minutes) limited its continued development. Our data warrant 
renewed interest in the development of FXIIIa inhibitors for the 
treatment and prevention of thrombosis. In particular, although 
total FXIII deficiency is associated with bleeding (32), Fibγ390–396A 
mice do not exhibit spontaneous bleeding or hemostatic defects, 
fully tolerate the abdominal surgery involved in the IVC thrombo-
sis models, and exhibit normal wound healing at the incision site. 
Thus, blocking the interaction between FXIII-A2B2 and fibrinogen 
or delaying FXIII activation are potentially safe approaches to re-
ducing venous thrombosis.
Our findings also have important clinical implications for man-
aging hemostasis. While congenital FXIII deficiency is rare, ac-
quired FXIII deficiency from surgical blood loss or inflammatory 
disease is more common but underdiagnosed due to the relative in-
sensitivity of standard tests. However, mounting evidence suggests 
patients with “mild” FXIII deficiency due to heterozygosity or sur-
gery have increased risk of bleeding (33). Consequently, the plasma 
level of FXIII required to maintain hemostasis in these patients is 
controversial. Our finding that FXIII mediates clot composition in a 
dose-dependent manner across the FXIII reference range suggests 
that 1 U/ml FXIII levels are required to achieve “normal” FXIII 
function and that even mildly reduced levels of FXIII can result in 
the formation of abnormal clots. Thus, maintaining higher concen-
trations of FXIII may decrease bleeding and improve wound heal-
ing in patients with congenital or acquired FXIII deficiency.
Essentially all FXIII-A2B2 circulates bound to fibrinogen 
(15), and following activation, FXIII-A2* crosslinks residues be-
mal (67 IU/kg, 1 IU/ml). FXIII-deficient clots exhibited reduced 
rbc retention following clot retraction (Figure 7A). Notably, rbc 
retention in FXIII-deficient human plasma was corrected by addi-
tion of FXIII-A2B2 in a dose-dependent manner (Figure 7A).
Finally, to determine whether blocking FXIII activity can re-
duce rbc retention and clot size, we treated normal human whole 
blood with the irreversible FXIII active site inhibitor T101 and 
induced clot formation and retraction. Following clot retraction, 
baseline levels of rbc present in serum exhibited interindividual 
variability (44.7% CV); however, for all donors, T101 produced a 
dose-dependent increase in serum rbc content (IC50 0.46 ± 0.07 
μM, Figure 7B), resulting in a 46% ± 8% reduction in clot size. 
These data show FXIII activity is a major determinant of clot rbc 
content and clot size in mice and humans.
Discussion
The discovery that FXIII(a) mediates rbc retention in venous 
thrombi redefines the pathophysiologic process that culminates in 
venous thrombus formation and reveals what may be a novel ther-
apeutic target to reduce venous thrombosis. We found that venous 
thrombus size is primarily determined by rbc content, suggesting 
venous thrombosis can be reduced by limiting rbc incorporation. 
We demonstrated that rbc retention in thrombi requires FXIII ac-
tivity. This finding indicates that rbc are not simply ensnared by 
the fibrin meshwork during thrombus formation, but that once 
present, they must be actively retained within the thrombus by this 
enzymatic activity during clot retraction. Our data reveal critical 
Figure 4. FXIII-A2B2 does not coprecipitate with Fibγ390–396A fibrinogen. (A) Blue silver–
stained 10% Tris-glycine gel containing purified fibrinogens from WT and Fibγ390–396A 
mice. Bands indicated with arrows were analyzed by mass spectrometry. (B) Western 
blot detection of FXIII-A subunit in purified fibrinogen (Fgn) samples shown in A and 
commercial murine FXIII as a positive control. (C) Relative level of FXIII-A in WT and 
Fibγ390–396A plasmas. Data represent means ± SEM (n = 4). (D) Relative binding curves of 
plasma-purified FXIII-A2B2 (Fibrogammin-P) to purified fibrinogen from WT or Fibγ
390–396A 
mice. Data represent normalized means ± SEM (n = 4).
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tween both the γ- and α-chains of fibrinogen. Smith et al. recently 
showed high-affinity binding of FXIII-A2B2 to a peptide contain-
ing amino acid residues 371–425 of the fibrinogen αC domain 
(34). However, since fibrinogen γ-chains are crosslinked prior 
to the α-chains, residues on the fibrinogen γ-chain would more 
efficiently fulfill the carrier function for FXIII-A2B2, with inter-
actions between FXIII-A2B2/FXIII-A2* and the αC region arising 
after initial interactions between FXIII-A2B2 and the γ-chain. Al-
though previous studies suggested FXIII-A2B2 binds preferential-
ly to a minor species of circulating fibrinogen containing an alter-
natively spliced C-terminal γ-chain (termed γʹ) (35), later studies 
demonstrated FXIII-A2B2 binds similarly to γ- and γʹ-containing 
recombinant fibrinogens (36). Our data indicate that mutations 
within fibrinogen residues γ390–396 decrease the coprecipita-
tion of FXIII-A2B2 with plasma fibrinogen and disrupt the inter-
action between FXIII-A2B2 and adherent fibrin(ogen), suggesting 
these residues mediate this carrier function and/or positioning 
of FXIII prior to crosslinking or cause a conformational change 
in fibrin(ogen) that reduces FXIII binding. Given that the γ-chain 
residues crosslinked by FXIII are immediately C-terminal to 
residues γ390–396, localization of FXIII-A2B2 at these residues 
would conveniently position FXIIIa for rapid crosslinking follow-
ing its activation. Subsequent contributions from the αC domain 
would facilitate crosslinking of α-chain residues following for-
mation of γ-γ dimers. Thus, one hypothesis consistent with these 
data is that the FXIII-A2B2 binding site is a composite between 
residues in the Aα- and γ-chains and that disrupting either site re-
duces binding. Alternately, FXIII may be “handed off ” between 
the fibrinogen γ-chain and the αC domain during its activation 
and activity. Further analysis of FXIII-A2B2 and FXIII-A2* inter-
Figure 5. Compared with WT, plasma from Fibγ390–396A mice exhibits delayed FXIII activation and, consequently, delayed fibrin crosslinking during tis-
sue factor–initiated coagulation. (A) Representative Western blots for FXIII-A during time course of tissue factor–initiated clotting in WT and Fibγ390–396A 
plasma. Activated FXIII (FXIII-A*) appears over time as a lower MW band. (B) Quantitation of FXIII-A* appearance over time in blots from A. Data represent 
mean ± SEM (n = 5). (C) Representative Western blots for fibrin(ogen) during time course of tissue factor–initiated clotting in WT and Fibγ390–396A plasma 
showing γ-γ dimer and high MW crosslinked species (α-α and α-γ polymers). (D) Quantitation of γ-γ dimer formation over time in Western blots. (E) Quan-
titation of high MW crosslinked species over time in Western blots. Data represent mean ± SEM (n = 6).
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actions with soluble fibrinogen and insoluble fibrin are warrant-
ed to discern the specific contributions of these residues to FXIII 
activation and activity.
Our data show that mutation of residues γ390–396 delayed, 
but did not abolish, FXIII activation and fibrin crosslinking. The ob-
served delay in FXIII activation and fibrin crosslinking was tempo-
rally associated with the timing of clot retraction (60–90 minutes). 
These findings imply the timing of fibrin formation, FXIII activa-
tion, crosslinking, and platelet-mediated clot retraction is orches-
trated to promote hemostasis and that altering the timing of these 
events leads to the formation of abnormal clots. The major targets 
of FXIII(a) activity are the fibrin γ- and α-chains, and FXIII(a)-me-
diated crosslinking of these fibrin chains imparts critical structural 
and mechanical properties to the fibrin network. Compared with 
uncrosslinked fibers, crosslinked fibers are thinner and more elas-
tic (37, 38) and require greater force to rupture (39). Compared with 
uncrosslinked clots, crosslinked clots have smaller pores, increased 
network density, and a higher viscoelastic storage modulus (ref. 38 
and reviewed in refs. 16, 40). It is currently unclear whether these 
effects directly mediate rbc retention during clot retraction. It is also 
possible that rbc themselves become crosslinked to the clot, either 
to fibrin or other clot-bound proteins or cells. FXIII has been shown 
to crosslink over 140 proteins in plasma (41), and the potential that 
FXIII(a) could crosslink proteins on the rbc surface has not been in-
vestigated. Further work to test these mechanisms is ongoing.
Thus far, genome-wide association studies have not associat-
ed FXIII SNPs with venous thrombosis. However, the most preva-
lent F13A coding polymorphism (Val34Leu) has been associated 
with decreased risk of venous thrombosis in a subset of studies 
(reviewed in ref. 42). In in vitro assays, the V34L polymorphism 
results in faster FXIII activation and is associated with denser fi-
brin structure and decreased permeability in clots made with low 
fibrinogen, but coarser fibrin structure and increased permeability 
in clots made with high fibrinogen (43, 44). However, the role of 
the Val34Leu polymorphism in thrombus formation or crosslink-
ing in vivo has not yet been determined. Together with our find-
ings, these observations suggest a complex relationship between 
FXIII activation kinetics and thrombus properties.
Although the prevailing paradigm suggests that rbc are nonin-
teracting and only incidentally present in thrombi, several lines of 
evidence suggest rbc actively promote clot formation and stability. 
Elevated levels of rbc are associated with increased risk of throm-
bosis in patients with polycythemia vera or patients on erythropoi-
etin (45–47), and increasing the hematocrit decreases the bleeding 
time in anemic patients (48–52). While this effect has been attrib-
uted to rbc-mediated margination of platelets within the vessels, 
rbc also support thrombin generation (53–55) and suppress plas-
min generation (56). Consequently, therapeutic approaches that 
limit thrombus rbc content may also indirectly reduce thrombus 
mass and stability. A recent study of experimental thrombosis 
showed thrombolysis is most effective in aged thrombi containing 
fewer intact rbc (57). These data suggest thrombus rbc content is 
a central determinant of thrombolytic success. Our finding that 
rbc retention in thrombi can be reduced by blocking FXIII activity 
provides a tool for investigating the specific contributions of rbc 
to venous thrombus formation and stability in vivo. Importantly, 
Figure 6. FXIII-deficient mice produce smaller thrombi with reduced rbc content. (A) Thrombus weights 1 day after ligation (stasis model). (B) Total 
neutrophil content of thrombus lysates, measured by Ly6G antigen. (C) Total platelet content of thrombus lysates, measured by CD41 antigen. (D) Total 
fibrin (β-chain) antigen of thrombus lysates. (E) Total rbc content of stasis thrombus lysates, measured as hemoglobin absorbance at 575 nm. Each dot 
represents an individual mouse. Lines are means. (F and G) Serum rbc content following thrombin-initiated clot retraction of recalcified blood from (F) 
F13a–/– (n = 4) and (G) Fibγ390–396A mice (n = 7). Data represent mean ± SEM.
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40 mM DTT and 12.5 mM EDTA at 
55°C overnight, and then mixed with 
6× reducing SDS-sample buffer.
All samples were separated on 
4% to 12% or 10% Tris-glycine gels 
(Novex) and transferred to PVDF 
membranes (Invitrogen). Mem-
branes were blocked for 1 hour at 
room temperature with Odyssey 
Blocking Buffer (LI-COR Bioscienc-
es) and incubated with primary anti-
bodies against Ly6G (rat anti-mouse 
clone RB6-8C5, 1:1500; eBioscienc-
es), CD41 (goat polyclonal, 1:500; 
Santa Cruz Biotechnology Inc.), 
spectrin α1 (rabbit polyclonal against 
spectrin α1 residues 541–650, 1:200; 
Santa Cruz Biotechnology Inc.), or 
fibrin (clone 59D8, 1:500; antibody 
provided by Charles Esmon, Okla-
homa Medical Research Foundation, Oklahoma City, Oklahoma, USA) 
overnight at 4°C. After washing, membranes were incubated with fluo-
rescence-labeled secondary antibodies for 1 hour at room temperature. 
Membranes were then washed and scanned using an Odyssey Infra-
red Imaging System (LI-COR Biosciences) or GE Typhoon FLA-9000 
Imager (GE Healthcare).
Thrombus rbc (hemoglobin) content. Thrombus lysates were diluted 
10-fold in 20 mM sodium phosphate (pH 7.4) and 150 mM NaCl (PBS); 
absorbance was measured at 575 nm.
Measurement of circulating TAT complexes. Postligation TAT lev-
els of PPP prepared from IVC blood draws were measured by ELISA 
(Enzygnost TAT microELISA; Siemens Healthcare Diagnostics Inc.).
Measurement of plasma thrombin generation. Plasma thrombin gen-
eration was measured in 6-fold diluted plasma by calibrated automat-
ed thrombography, as described (60).
Clot retraction assays. Blood was drawn from mice into 3.2% sodi-
um citrate (10% v/v, final concentration) and corn trypsin inhibitor 
(CTI) (18.3 μg/ml final concentration). For whole-blood clot retrac-
tion, blood was used undiluted or was diluted 3-fold in HEPES-
buffered saline (HBS; 20 mM HEPES, pH 7.4, 150 mM NaCl), in the 
absence or presence of the FXIII inhibitor T101 (0–200 μM, final con-
centration; Zedira) as indicated. For PRP clot retraction, blood was 
centrifuged twice (150 g, 5 minutes), and PRP was collected and used 
undiluted. Clotting was triggered in recalcified (10 mM, final concen-
tration) whole blood or PRP by addition of tissue factor (Innovin dilut-
ed to 1:12,000, 1 pM, final concentration) or thrombin (2 U/ml bovine 
thrombin, final concentration), as indicated. In all experiments, clot-
ting and subsequent retraction proceeded at 37°C for 90 minutes in 
siliconized glass tubes. Retracted clots were imaged to determine final 
percentage of retraction. Serum was collected, and rbc were measured 
by directly counting cells on a HV950FS Hemavet cell counter (Drew 
Scientific) or by diluting serum 10- to 200-fold in HBS, measuring 
absorbance at 575 nm, and comparing with a standard curve of diluted 
rbc enumerated with a Hemavet cell counter. To confirm that whole 
rbc were released from clots, serum was centrifuged (100 g, 10 min-
utes) to pellet extruded intact rbc, and the free hemoglobin content 
of the residual serum (absorbance at 575 nm) was compared with that 
our findings redefine the paradigm determining venous thrombus 
composition and size, and identify a therapeutic target for pre-
venting venous thrombosis.
Methods
Mice. Fibγ390–396A mice (4) and F13a–/– mice (24) were independently back-
crossed 6 generations to a C57BL/6J background. CD11b–/– mice (21), also 
on a C57BL/6 background, were backcrossed more than 7 generations.
Murine venous thrombosis models. The IVC stasis model was per-
formed on 8- to 10-week-old male WT, Fibγ390–396A, F13a–/–, and F13a+/+ 
mice as described (58, 59). Briefly, anesthetized mice were subject to 
sterile laparotomy and exposure of the IVC. Side branches were ligat-
ed, and lumbar branches were closed by cautery. The IVC was separat-
ed from the aorta by blunt dissection and completely ligated. The IVC 
stenosis model was performed as described (19). Briefly, side branches 
were ligated, but no lumbar branches were cauterized. Stenosis was 
achieved by partial ligation of the IVC using a 30-gauge needle as a 
temporary spacer during ligation, after which it was removed. Mice 
recovered with analgesia (buprenorphine, 0.05 mg/kg, subcutaneous) 
and were maintained on acetaminophen (6 mg/ml) in their drinking 
water after surgery. After 24 hours, mice were anesthetized and blood 
drawn from the suprarenal IVC into 3.2% sodium citrate (10% v/v, 
final concentration). Blood samples were centrifuged at 5,000 g for 
10 minutes to prepare platelet-poor plasma (PPP). Thrombi were sepa-
rated from the vein wall, weighed, and frozen.
Thrombus analysis by Western blot. Frozen thrombus samples from 
WT, Fibγ390–396A, F13a+/+, and F13a–/– mice were homogenized in lysis 
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
β-glycerophosphate, 1 mM Na3VO4, and 1 mg/ml leupeptin; Cell Signal-
ing) supplemented with 1 mM PMSF using a Dounce Tissue Homog-
enizer (Bellco Glass). Thrombus lysates were kept on ice for 1 hour 
before centrifugation (7,000 g, 15 minutes) at 4°C. Supernatants were 
collected and mixed with 6× nonreducing SDS-sample buffer (Bos-
ton BioProducts). Nonreduced samples were used for blotting leuko-
cyte (Ly6G) and platelet (CD41) antigens. For a subset of samples, the 
crosslinked fibrin enriched pellet was dissolved in 8 M urea containing 
Figure 7. FXIII-deficient human clots retain fewer rbc after clot retraction, and FXIII inhibition prevents rbc 
retention in clots. (A) Serum rbc content following tissue factor–initiated clot retraction of human FXIII-defi-
cient patient plasma reconstituted with washed platelets and washed rbc from normal donors and treated with 
increasing doses of FXIII (0–1 U/ml, n = 6). Data represent mean ± SEM. *P < 0.02 versus FXIII-deficient plasma 
with no additional FXIII by ANOVA. (B) Serum rbc content following tissue factor–initiated clot retraction of nor-
mal human whole blood in the presence of the irreversible FXIIIa inhibitor, T101 (0.1–5 μM, n = 7). Data represent 
normalized mean ± SEM. *P < 0.02 versus absence of T101 by ANOVA.
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series of Fibrogammin-P (1.95 μM to 0.2 pM). Wells were probed with 
sheep anti-human FXIII-A subunit antibody (1:1000) and HRP-con-
jugated donkey anti-sheep secondary (1:10,000; Sigma-Aldrich). All 
incubation steps were performed for 1 hour at room temperature and 
followed by washing with HBS/Ca2+ containing 0.5% Tween 20. ELISAs 
were developed with SureBlue peroxidase substrate (KPL), and gen-
eration of blue color was monitored at 600 nm with a SpectraMax 
340PC microplate reader. The maximum rate of substrate cleavage 
was determined using SoftMax software.
Plasma clot formation and detection of FXIIIa and crosslinked fibrin. 
PPP from WT and Fibγ390–396A mice was recalcified (10 mM, final con-
centration) and clotted with tissue factor (1 pM, final concentration). 
At indicated time points, quenching solution (50 mM DTT, 12.5 mM 
EDTA, 8 M urea) was added. Samples were then incubated at 60°C for 
1 hour with occasional agitation. Samples were reduced, boiled, sepa-
rated on 10% Tris-glycine gels, and transferred to PVDF membranes. 
Membranes were probed with rabbit anti-human fibrinogen poly-
clonal antibodies (rabbit anti-fibrin[ogen]). Membranes were then 
stripped with 10 mM DTT in 7 M guanidine for 20 minutes at 60°C 
and reprobed with sheep anti-human FXIII-A polyclonal antibody. 
Band intensity (AU) was measured by densitometry using Photoshop 
CS6 version 13.0. Bands were normalized to initial intensity at time 0 
with the following exceptions: FXIII-A* was normalized to FXIII-A at 
time 0, γ-γ dimers were normalized to γ-chain at time 0, and high MW 
crosslinked species were normalized to α-chain at time 0.
Clot retraction of reconstituted human FXIII-deficient blood. Normal 
and FXIII-deficient plasmas were prepared from blood drawn from 
consenting healthy individuals and a patient with FXIII deficiency. 
The patient was a 7-year-old female with severe congenital deficiency 
of FXIII (<5%) who received prophylactic FXIII concentrate infusions 
every 4 weeks. The blood sample was obtained before an infusion when 
the trough level was 14%. rbc and platelets were isolated from blood 
drawn from consenting healthy donors into 3.2% citrate (10% v/v, 
final concentration) and CTI (18.3 μg/ml, final concentration) and cen-
trifuged (150 g, 20 minutes). The PRP fraction was treated with pros-
taglandin-I2 (50 ng/ml, final concentration) and centrifuged (400 g, 
20 minutes). Pelleted platelets were resuspended in Tyrode’s buffer 
(15 mM HEPES, 3.3 mM NaH2PO4, pH 7.4, 138 mM NaCl, 2.7 mM KCl, 
1 mM MgCl2, 5.5 mM dextrose), allowed to rest for 30 minutes at 37°C, 
counted on a Hemavet, and diluted to 1 million/μl. After removing 
the buffy coat, the rbc fraction was washed 3 times with CGS buffer 
(1.29 mM sodium citrate, 3.33 mM glucose, 124 mM NaCl, pH 7.2), 
centrifuged (400 × g, 5 minutes), resuspended in HBS, and packed by 
centrifugation (400 × g, 10 minutes). Packed rbc were diluted 2-fold 
in HBS and counted on a Hemavet. Plasma-derived FXIII-A2B2 (Fibro-
gammin-P) or HBS was incubated with citrated normal and FXIII-defi-
cient plasmas (no CTI) for 10 minutes at room temperature. Washed 
platelets (100,000/μl, final concentration) and rbc (4–5 million/μl, 
final concentration) were combined with plasmas in siliconized wells 
of a 96-well plate containing tissue factor (1 pM, final concentration) 
and CaCl2 (10 mM, final concentration). Clot formation and retraction 
were allowed to proceed for 90 minutes at 37°C. rbc content of serum 
was measured by absorbance as described above.
Statistics. Descriptive statistics (mean, median, SD, SEM) were 
calculated for each condition, and Lilliefors test was used to assess nor-
mality. Data were compared by Student’s t test with equal or unequal 
variance, as appropriate, for experiments with 2 groups. ANOVA was 
of the plasma from corresponding whole blood (prior to clot initiation 
and retraction) from WT and Fibγ390–396A mice. This analysis showed 
less than 0.2% of total rbc hemolysis, confirming that rbc extruded 
from whole blood clots during clot retraction in vitro were intact. 
Retracted clots were also collected and weighed.
rbc washout assay in the absence of platelets. Blood was drawn from 
mice into 3.2% sodium citrate (10% v/v, final concentration) and cen-
trifuged (250 g, 10 minutes). PRP fractions were separated and pro-
cessed to PFP by sequential centrifugation (2000 g for 15 minutes, 
followed by 7000 g for 10 minutes). The buffy coat was removed 
from the rbc fraction and washed 3 times in 1.29 mM sodium citrate, 
3.33 mM glucose, and 124 mM NaCl (pH 7.2) and was centrifuged 
(250 g, 5 minutes). rbc were resuspended in PBS with 0.1% BSA and 
centrifuged (500 g, 10 minutes) to pack cells. Packed rbc (4 μl) were 
added for every 100 μl PFP. Flow cytometry of PFP and washed rbc 
revealed less than 0.01% and 10% platelet contamination (percent-
age of initial platelet count by GPIX-positive events) in PFP and rbc, 
respectively. The initial absorbance of rbc-PFP mix was determined 
by 50-fold dilution in PBS. rbc-PFP mix was clotted with tissue factor 
(1 pM, final concentration) and CaCl2 (10 mM, final concentration) 
at room temperature. After 1 hour, 700 μl HBS was added and absor-
bance at 575 nm was measured and used to calculate percentage of 
change from initial absorbance.
Isolation of fibrinogen from plasma with glycine precipitation. PPP 
was supplemented with 10 mM PMSF and 5 mM benzamidine (final 
concentration). Glycine (165 mg per ml plasma) was added, and sam-
ples were rotated at room temperature for 1 hour. The precipitate was 
collected via centrifugation and resuspended in HBS before repre-
cipitation with glycine. The precipitate was resuspended in HBS and 
assessed by SDS-PAGE. Samples were stored at –80°C.
rbc adhesion assay. Microfluidic channels (43.5 × 500 μm in cross-
section) were coated with 10 μg/ml BSA, purified WT fibrinogen, or 
Fibγ390–396A fibrinogen for 2 hours at room temperature and then rinsed 
with PBS. Washed, packed rbc from WT mice were diluted 100-fold 
in PBS (~20,000/μl), loaded into channels, and allowed to adhere for 
10 minutes under static conditions. PBS was then flowed through the 
channels at 1000 s–1 for 5 minutes. Bright field images of the channels 
before and after flow were captured on an Olympus IX81 inverted light 
microscope with a ×40 objective. Percentage of adhesion was mea-
sured by counting cells using ImageJ software.
Mass spectrometry–based identification of FXIII in WT fibrinogen.  
Purified fibrinogen was reduced and separated on a 10% Tris-gly-
cine gel. Bands were visualized by colloidal blue silver stain (61), 
excised, and analyzed by the Michael Hooker University of North 
Carolina Proteomics Center using a MALDI TOF/TOF 4800 Mass 
Analyzer (ABSciex).
Detection of FXIII in murine plasma. PPP was diluted 1:120 in water 
and added 5:1 to reducing SDS–sample buffer. Samples were separated 
on a 10% Tris-glycine gel and transferred to PVDF membranes. West-
ern blotting was performed as above, using sheep anti–FXIII-A subunit 
polyclonal antibody (1:1000; Enzyme Research Laboratories) and rab-
bit anti–FXIII-B subunit polyclonal antibody (1:1000; Sigma-Aldrich).
ELISA for FXIII binding to adherent fibrinogen. Purified mouse 
fibrinogen (0.029 μM diluted in HBS containing 1 mM CaCl2 [HBS/
Ca2+]) was coated onto a Corning 96-well high-binding microplate. 
Control wells were coated with HBS/Ca2+ alone. Wells were blocked 
with HBS/Ca2+ containing 0.1% BSA and incubated with a 1:5 dilution 
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